Serum peroxiredoxin 4: A marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC-28)

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Gerrits, Esther G ^a,b   Alkhalaf, Alaa ^b   Landman, Gijs W D ^b   Van Hateren, Kornelis J J ^b,c   Groenier, Klaas H ^b,d   Struck, Joachim ^e   Schulte, Janin ^e   Gans, Reinold O B ^d   Bakker, Stephan J L ^d   Kleefstra, Nanne ^b,c,d   Bilo, Henk J G ^b,d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN; PEROXIREDOXIN 4; BIOLOGICAL MARKER; PEROXIREDOXIN;

AGE; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; BLOOD; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODEL;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; OXIDATIVE STRESS; PEROXIREDOXINS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84896137716     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089719     Document Type: Article

References (26)

1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, et al. (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30: 162-172. (Pubitemid 46052519)
2. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34: 3035-87.
3. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
4. Rains JL, Jain SK (2011) Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 50: 567-575.
5. Yan SF, Ramasamy R, Schmidt AM (2010) The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106: 842-53.
6. Rolo AP, Palmeira CM (2006) Diabetes and Mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212: 167-178.
7. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107: 1058-1070.
8. Wood ZA, Schröder E, Harris JR, Poole LB (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40. (Pubitemid 36051004)
9. Valko M, Leibfritz D, Moncol J, Cronin M, Mazur M, et al. (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84. (Pubitemid 44566469)
10. 2 produced during disulphide formation. J Cell Science 123: 2672-2679.
11. Fujii J, Ikeda Y (2002) Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123-130. (Pubitemid 34700435)
12. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, et al. (2002) Proteomics analysis of cellular response to oxidative stress: evidence for in vivo over-oxidation of peroxiredoxins at their active site. J Biol Chem 277: 19396-19401. (Pubitemid 34967447)
13. Ding Y, Yamada S, Wang KY, Shimajiri S, Guo X, et al. (2010) Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxid Redox Signal 13: 1477-1490.
14. Okado-Matsumoto A, Matsumoto A, Fujii J, Taniguchi N (2000) Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J Biochem 127: 493-501. (Pubitemid 30185255)
15. Xie X, Li S, Liu S, Lu Y, Shen P, Ji J (2008) Proteomic analysis of mouse islets after multiple low-dose streptozotocin injection. Biochim Biophys Acta 1784: 276-284.
16. Dreja T, Jovanovic Z, Rasche A, Kluge R, Herwig R, et al. (2010) Diet-induced gene expression of isolated pancreatic islets from a polygenic mouse model of the metabolic syndrome. Diabetologia 53: 309-320.
17. Jiang YL, Ning Y, Ma XL, Liu YY, Wang Y, et al. (2011) Alteration of the proteome profile of the pancreas in diabetic rats induced by streptozotocin. Int J Mol Med 28: 153-160.
18. Schulte J, Struck J, Bergmann A, Köhrle J (2010) Immunoluminometric assay for quantification of peroxiredoxin 4 in human serum. Clin Chim Acta 411: 1258-1263.
19. Schulte J, Struck J, Köhrle J, Müller B (2011) Circulating levels of peroxiredoxin 4 as a novel biomarker of oxidative stress in patients with sepsis. Shock 35: 460-465.
20. Chang X, Cui Y, Zong M, Zhao Y, Yan X, et al. (2009) Identification of proteins with increased expression in rheumatoid arthritis synovial tissues. J Rheumatol 36: 872-880.
21. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, et al. (2012) Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. J Am Heart Assoc 1: e002956.
22. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, et al. (2003) Prevalence, incidence and mortality of type 2 diabetes mellitus revisited. A prospective population-based study in The Netherlands (ZODIAC-1). Eur J of Epidemiol 18: 793-800. (Pubitemid 37039978)
23. May S, Hosmer DW (1998) A simplified method of calculation an overall goodness of-fit test for the Cox proportional hazards model. Lifetime Data Anal 4: 109-120. (Pubitemid 128480552)
24. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387. (Pubitemid 26072233)
25. Pencine MJ, D'Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48: 1703-1711.
26. Nickel CH, Ruedinger J, Misch F, Blume K, Maile S, et al. (2011) Copeptin and Peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency department. Acad Emerg Med 18: 851-859.